With the investment, Lauxera Capital Partners is joining with other investors, majority owner Bure Equity AB and Northislet AB, as well as with BioLamina’s founders and executives as shareholders in support of the company’s mission.
“The BioLamina team is excited to welcome Lauxera to our committed group of shareholders and to our Board of Directors, and we look forward to leveraging the Lauxera team’s experience and insights into our markets. Throughout the transaction process it has become clear that they share our passion for supporting both academic pioneers and trailblazing biotech visionaries in their quest to provide life-changing solutions,” says Veronica Byfield Sköld, CEO at BioLamina.
Its next leg of growth
This is the tenth investment made by Lauxera Growth I, a growth and growth buy-out fund dedicated to investing primarily in commercial-stage European Healthtech businesses. As part of the investment, Alex Slack, co-founder of Lauxera, will join BioLamina’s Board of Directors.
“The entire team at Lauxera could not be more excited to partner with BioLamina in advancing the stem cell field as it delivers breakthroughs in regenerative medicine and in disease research. BioLamina stands at the fulcrum of inflection points in two attractive end markets, with a strong and dedicated executive team, talented employees, and a convicted investor base. We are humbled by the responsibility to help BioLamina achieve its next leg of growth, adding to and enhancing its global footprint, manufacturing and regulatory capabilities, and customer intimacy,” says Alex Slack, co-founder of Lauxera Capital Partners.
Photo of Veronica Byfield Sköld: Patrick Degerman/Impilo